The Technion – Israel Institute of Technology, alongside the Alfred Mann Institute (AMIT) have founded a company aimed to commercialize stem cell technology developed over the past decade by Professor Joseph Itskovitz-Eldor of the Rappaport institute. The new company, named Accellta, will market technologies and methods which will assist commercial companies and research labs in cultivating stem cells quickly, efficiently and aconomically.
Tagged: stem cell RSS Toggle Comment Threads | Keyboard Shortcuts
Pharmaceutical giant Pfizer is in contact with Israeli companies Gamida Cell and TEVA, with intent of commercializing Gamida Cell’s StemEX, a treatments for lymphoma and leukemia (which is partially owned by TEVA). Israeli economics magazine Calcalist reports that if the deal goes through, Gamida cell will receive tens of millions of dollars in advance plus grants for milestones reached. Gamida Cell specializes in developing stem cell therapy projects.
Israeli company Gamida Cell announced today that it has closed an internal financing round of $10 million from all major shareholders. According to the company, the financing will be used to support the global commercialization of the company’s lead cell therapy product, StemEx. The product is in development as an alternative therapeutic treatment for patients with blood cancers, such as leukemia and lymphoma who can be cured by bone marrow transplantation but do not have a matched bone marrow donor.
Kadimastem, an Israeli biotechnology company that develops human pluripotent stem cell-related products, announced the signing of a five year framework agreement with Merck Serono. The agreement concerns the use of Kadimastem’s drug-screening platform to discover new oral drugs for the treatment of the neurological disease Multiple Sclerosis (MS). The company is based in Nes-Ziona, Israel.